Available for over a yearIn the 1980s, scientists made a discovery that would eventually lead to the development of drugs now used worldwide to treat diabetes and to help people...

People with thyroid eye disease receiving infusions of the insulin-like growth factor-1 receptor veligrotug report improved quality of life after 15 weeks of treatment. Medscape Medical News Source link :...

From intensifying therapy in ctDNA-positive bladder cancer to scaling it back in ctDNA-negative colon cancer, new data from ESMO 2025 signal a shift toward precision-guided adjuvant care. Medscape Medical News...

An illustration of CAR T-cell therapy treating tumour cellsBrain light/Alamy Immune cells that have been genetically engineered to kill cancerous cells, known as CAR T-cells, have transformed the treatment of...

Nick TriggleHealth correspondentGetty ImagesHealth checks would include asking women about menopause symptoms, though exact questions have yet to be decidedMenopause screening is to be officially incorporated into NHS health checks...

Helen LedwickWhen Helen Ledwick typed "why do my insides feel like they're falling out" into Google a decade ago, she had no idea that search would mark the beginning of...

Evidence is mounting that GLP-1 drugs like Wegovy do far more than treat obesity and type 2 diabetesShelby Knowles/Bloomberg via Getty Images The weight-loss drug Wegovy curbs the risk of...

(MedPage Today) -- Gum disease was linked with white matter hyperintensities, an imaging marker of cerebral small vessel disease, data from the Atherosclerosis Risk in Communities (ARIC) cohort showed. Among...

(MedPage Today) -- BERLIN -- A single infusion of the investigational PRAME-directed T-cell receptor T-cell therapy anzutresgene autoleucel (anzu-cel) showed encouraging antitumor activity in patients with previously treated advanced or...

(MedPage Today) -- A public health group and a top-tier journal will partner to publish an alternative to the CDC's flagship weekly publication that has been diminished under the Trump...

(MedPage Today) -- Patients with lupus nephritis were more likely to get off chronic corticosteroid treatment, and stay off, when certain factors were in place, researchers said. Achieving renal remission...

(MedPage Today) -- EAST RUTHERFORD, N.J. -- Jaxson Dart was getting checked for a concussion during the New York Giants' prime-time game against Philadelphia, and Brian Daboll was running out...

(MedPage Today) -- In updated clinical guidance, the American College of Obstetricians and Gynecologists (ACOG) urged physicians to speak out in support of access to contraception. The group's statement on...

(MedPage Today) -- CHICAGO -- Novel orexin receptor 2 agonist oveporexton normalized wakefulness for most people with narcolepsy type 1 in two randomized phase III trials. Mean sleep latency across...

(MedPage Today) -- ATLANTA -- For patients with cardiovascular implantable electronic device (CIED)-associated infections, a shorter course of antibiotics after lead extraction may be noninferior to a longer course for...

(MedPage Today) -- The FDA is requiring stronger warnings for tranexamic acid (TXA) injection to avoid medication errors following reports of serious injury, including death. "FDA is taking this action...

(MedPage Today) -- Antidepressant side effects vary widely by drug, a network meta-analysis showed. (The Lancet) Children's Hospital Colorado reported a 73% rise in the use of its eating disorders...

(MedPage Today) -- ORLANDO -- Among children taking the monoclonal antibody dupilumab (Dupixent) for atopic dermatitis, more than a quarter of ocular complications developed after a year, according to a...

Peter Betts (seated, pink shirt) at COP17 in Durban, South Africa, in 2011IISD/ENB Leila Mead The Climate DiplomatPeter Betts, Profile Editions Climate negotiators, lobbyists and world leaders will descend on...

A shot from the Growing the Next Era of Fashion section at Material WorldInes Stuart-Davidson/RBG Kew As a lover of fashion, I was intrigued to visit Material World, the first...